Wearable cardioverter-defibrillator in patients with a transient risk of Sudden cardiac death: the WEARIT-France cohort study

Rodrigue Garcia, Nicolas Combes, Pascal Defaye, Kumar Narayanan, Laurence Guedon-Moreau, Serge Boveda, Hugues Blangy, Jérôme Bouet, Florent Briand, Philippe Chevalier, et al.

To cite this version:
Rodrigue Garcia, Nicolas Combes, Pascal Defaye, Kumar Narayanan, Laurence Guedon-Moreau, et al.. Wearable cardioverter-defibrillator in patients with a transient risk of Sudden cardiac death: the WEARIT-France cohort study. EP-Europace, Oxford University Press (OUP), 2020, 10.1093/europace/euua268. hal-03037854

HAL Id: hal-03037854
https://hal.archives-ouvertes.fr/hal-03037854

Submitted on 5 Jan 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Wearable cardioverter-defibrillator in patients with a transient risk of Sudden cardiac death: the WEARIT-France cohort study

Rodrige Garcia 1,2, Nicolas Combes 3, Pascal Defaye 4, Kumar Narayanan 5,6,7, Laurence Guedon-Moreau 8, Serge Boveda 9, Hugues Blangy 10, Jérôme Bouet 11, Florent Briand 12, Philippe Chevalier 13, Yves Cottin 14, Antoine Da Costa 15, Bruno Degand 1, Jean-Claude Deharo 16, Romain Eschalier 17, Fabrice Extramiana 18, Marc Goralski 19, Benoît Guy-Moyat 20, Yves Guymar 21, Jean-Sylvain Hermida 22, François Jourda 23, Nicolas Lellouche 24, Mohanad Mahfoud 25, Vladimir Manenti 26, Jacques Mansourati 27, Angéline Martin 28, Jean-Luc Pasquié 29, Philippe Ritter 30, Anne Rollin 31, Thierry Tibi 32, Arab Yalioua 33, Daniel Gras 34, Nicolas Sadoul 10, Olivier Piot 35, Christophe Leclercq 36, and Eloï Marijon 5,6,8, on behalf of the WEARIT-France Investigators

1Department of Cardiology, Poitiers University Hospital, 86021 Poitiers, France; 2Univ Poitiers, 86000 Poitiers, France; 3Department of Cardiology, Pasteur Clinic, 33000 Toulouse, France; 4Department of Cardiology, Grenoble University Hospital, 38043 Grenoble, France; 5Department of Cardiology, European Georges Pompidou Hospital, 75015 Paris, France; 6University of Paris, PARCC, INSERM, F-75015 Paris, France; 7Cardiology Department, Medicover Hospitals, Hyderabad, India; 8Department of Cardiology, Lille University Hospital, 59000 Lille, France; 9Department of Cardiology, Pasteur Clinic, 33000 Toulouse, France; 10Department of Cardiology, Nancy University Hospital, 54500 Vandoeuvre-Lès-Nancy, France; 11Department of Cardiology, Hospital Center of Aix, 13080 Aix En Provence, France; 12Department of Cardiology, Besançon University Hospital, 25000 Besançon, France; 13Department of cardiology, Lyon University Hospital, 69000 Lyon, France; 14Department of Cardiology, Dijon University Hospital, 21000 Dijon, France; 15Department of Cardiology, Saint-Etienne University Hospital, 42000 Saint-Étienne, France; 16Department of cardiology, University Hospital La Timone, 13000 Marseille, France; 17Department of cardiology, Clermont-Ferrand University Hospital, 63000 Clermont Ferrand, France; 18Department of Cardiology, Bichat Hospital - Claude Bernard, 75877 Paris, France; 19Department of Cardiology, General Hospital of Orléans, 45000 Orléans, France; 20Department of Cardiology, Limoges University Hospital, 87000 Limoges, France; 21Department of Cardiology, Hospital Center Saint Philbert, 59160 Lommé, France; 22Department of Cardiology, Amiens University Hospital, Amiens, France; 23Department of Cardiology, General Hospital of Auxerre, 89000 Auxerre, France; 24Department of Cardiology, University Hospital Henri Mondor, 94000 Créteil, France; 25Department of Cardiology, Hospital Center Sud Francilien, 91100 Corbeil Essonnes, France; 26Department of Cardiology, Jacques Cartier Institute, 91800 Massy, France; 27Department of Cardiology, Brest University Hospital, 29200 Brest, France; 28Department of Cardiology, Fontaine Clinique, 21211 Fontaine-Lès-Dijon, France; 29Department of Cardiology, Montpellier University Hospital, 34000 Montpellier, France; 30Cardiology Department, Bordeaux University Hospital, 33600 Pessac, France; 31Department of Cardiology, Toulouse University Hospital, 31000 Toulouse, France; 32Department of Cardiology, General Hospital of Cannes, 06150 Cannes, France; 33Department of Cardiology, General Hospital of Angoulême, 16000 Angoulême, France; 34Department of Cardiology, Hospital privé du Confluent, 44000 Nantes, France; 35Department of Cardiology, Cardio Center of Nord, 92300 Saint Denis, France; and 36Department of Cardiology, Rennes University Hospital, 35000 Rennes, France

Received 31 March 2020; editorial decision 9 August 2020; accepted after revision 14 August 2020

Aims

We aimed to provide contemporary real-world data on wearable cardioverter-defibrillator (WCD) use, not only in terms of effectiveness and safety but also compliance and acceptability.

Methods and results

Across 88 French centres, the WEARIT-France study enrolled retrospectively patients who used the WCD between May 2014 and December 2016, and prospectively all patients equipped for WCD therapy between January 2017 and March 2018. All patients received systematic education session through a standardized programme across France at the time of initiation of WCD therapy and were systematically enrolled in the LifeVest Network remote services. Overall, 1157 patients were included (mean age 60 ± 12 years, 16% women; 46% prospectively): 82.1% with ischaemic cardiomyopathy, 10.3% after implantable cardioverter-defibrillator explant, and 7.6% before heart transplantation. Median WCD usage period was 62 (37–97) days. Median daily wear time of WCD was 23.4 (22.2–
23.8) h. In multivariate analysis, younger age was associated with lower compliance [adjusted odds ratio (OR) 0.97, 95% confidence interval (CI) 0.95–0.99, \( P < 0.01 \)]. A total of 18 participants (1.6%) received at least one appropriate shock, giving an incidence of appropriate therapy of 7.2 per 100 patient-years. Patient-response button allowed the shock to be aborted in 35.7% of well-tolerated sustained ventricular arrhythmias and in 95.4% of inappropriate ventricular arrhythmia detection, finally resulting in an inappropriate therapy in eight patients (0.7%).

**Conclusion**

Our real-life findings reinforce previous studies on the efficacy and safety of the WCD in the setting of transient high-risk group in selected patients. Moreover, they emphasize the fact that when prescribed appropriately, in concert with adequate patient education and dedicated follow-up using specific remote monitoring system, compliance with WCD is high and the device well-tolerated by the patient.

**Graphical Abstract**

What’s new?

- Two percent of patients received at least one appropriate shock and <1% received an inappropriate shock. Response button, in aborting 95% of shocks in case of arrhythmia misclassification, is a key factor in this very low rate of inappropriate therapies.
- Younger age was associated with lower compliance and this should be considered carefully when educating the patient.
- When prescribed appropriately, in concert with adequate patient education and dedicated follow-up using specific remote monitoring system, compliance with wearable cardioverter-defibrillator is high and the device well-tolerated by the patient.

**Introduction**

Sudden cardiac death (SCD) is a major mode of death accounting for ~600 000 fatalities in Europe every year. Sudden cardiac death constitutes ~50% of all cardiac mortality and delay between cardiac arrest onset and arrhythmia termination is a major determinant of survival. Since SCD risk may sometimes be transient, the wearable cardioverter-defibrillator (WCD) has been developed as a proposed solution for short-term risk mitigation in such situations.

The Prospective Registry of Patients using the Wearable Defibrillator (the WEARIT-II Registry) and the German National Registry have emphasized the safety and efficacy of WCD in large cohorts of patients. The reported first randomized controlled trial testing the potential benefit of WCD after myocardial infarction (VEST trial) did not show a significant difference in sudden death between the WCD and the control arms but a significant survival benefit was found. The VEST study highlighted the importance of patient compliance with the WCD for it to be effective. Presently, there are relatively few few data on adherence to WCD use and influencing factors, and the extent to which shock interruption by use of the response button by the patient may avoid inappropriate shocks has never been assessed.

The French National Study, WEARIT-France, was designed to evaluate contemporary real-world data on WCD use in France, not only in terms of effectiveness and safety but also compliance and acceptability.
Methods

Study design and patient population
WEARIT-France study (Clinical Trials.gov Identifier: NCT03319160) was comprised of a retrospective and a prospective phase across 88 French cardiology centres. All patients who had already completed the use of a WCD (LifeVest system, ZOLL, Pittsburgh, PA, USA) between May 2014 and December 2016 were invited to participate in the retrospective part. The prospective phase was carried out between January 2017 and March 2018. Patients receiving a WCD during a clinical appointment were offered participation in the prospective part of the study. This study complies with the Declaration of Helsinki and an ethics committee has approved the research protocol. All patients who agreed to participate were entered into the study after having given their informed consent.

According to French Social Security and healthcare reimbursement, the criteria for WCD prescription were one of the following: implantable cardiac-defibrillator (ICD) removal due to device infection, bridge to heart transplantation, and ischaemic cardiomyopathy with left ventricular ejection fraction (LVEF) <30% in the settings of early post-myocardial infarct or after a recent coronary revascularization.

The wearable cardioverter-defibrillator
The WCD technology used in the WEARIT-France study is a commercially available external defibrillator (LifeVest, Zoll Systems, PA, USA), guided by an algorithm to detect ventricular tachyarrhythmia events. The functioning of WCD has been already described.4

The LifeVest Network
During the index hospitalization when WCD therapy was initiated, the treating physician systematically assessed the appropriateness of WCD prescription and educated the patient regarding the transient risk for SCD, functioning of the WCD, and benefits expected from the device. Additionally, just before discharge, a technical expert from the WCD company imparted a practical education to the patient, encompassing the nature of the disease, indication for WCD, alarm management, battery recharging, and remote transmission.

Collected data and study endpoints
At the time of enrolment, medical history, comorbidities, symptoms, and other baseline characteristics were collected in addition to the indication for WCD. Device information extracted included wear time, therapies delivered with associated EGMs, and response button utilization. Stored EGMs related to the utilization of the response button were reviewed by the independent adjudication committee, and categorized as episodes of well-tolerated sustained ventricular arrhythmia or inappropriate ventricular arrhythmia detection. Only sustained (i.e. >30s) ventricular tachycardia (VT)/ventricular fibrillation (VF), atrial fibrillation, atrial flutter, supraventricular tachycardia, bradycardia, and asystole (heart rate <10 b.p.m. during 16s) were automatically collected.

The main endpoints were centrally adjudicated by an independent clinical events committee composed of three experts who adjudicated the events, by analysing the EGM data independent of each other and blinded to any additional information. The primary endpoint was appropriate therapy, which was defined as shocks delivered for adjudicated sustained (>30s) VT or VF episodes. Inappropriate shocks were defined as shocks delivered for all episodes other than sustained VT or VF. The incidence was calculated as the number of appropriate or inappropriate shocks/100 patient-years.

Compliance was evaluated through daily use, defined as hours per day of use during the wearing period. Adherence to WCD and the health status of patients was assessed in 202 (38%) patients of the prospective cohort, at 30 days using a questionnaire, developed specifically to evaluate the acceptability of WCD therapy.10 Items on the survey asked the patient to indicate their agreement using the five-point Likert agreement response scale (Strongly agree, Agree, Neither agree nor disagree, Disagree, Strongly disagree) with respect to the following topics related to their use of the WCD: peace of mind, worry, sleep quality, confidence in returning to activities of daily living, confidence to exercise or perform cardiac rehabilitation, taking their disease condition seriously, improved self-care, change in lifestyle modification, and whether they would recommend the WCD to other patients.

Statistical analysis
Preparation of this report was carried out in accordance with the STrengthening the Reporting of Observational studies in Epidemiology (STROBE) statement.11 Data collection and analysis were conducted independent of the WCD manufacturer by ClinSearch (Paris, France) and CRI (Munich, Germany). Descriptive statistics were used to report major clinical characteristics, incidence, and frequency of appropriate and inappropriate shocks. Continuous variables were expressed as mean and standard deviation when normally distributed and compared using the Student’s t-test; and expressed as median and interquartile range, when not normally distributed, and compared using Wilcoxon–Mann–Whitney non-parametric test. Nominal variables were expressed as number and percentage and compared using the Pearson’s χ² test or Fisher’s exact test, as appropriate. Sensitivity analyses were performed according to the period of inclusion (retrospective vs. prospective).

For analysis of WCD compliance, daily wear duration was arbitrarily categorized as < or ≥20h. Logistic regression was used to identify significant factors associated with non-compliance. Analyses were performed using R software (version 3.5.3). All statistical tests performed were two-sided. A P-value of <0.05 was considered statistically significant.

Results

Baseline patient characteristics
A total of 1157 patients were included in the WEARIT-France study. Among them, 628 (54.3%) were retrospectively included and 529 (45.7%) were prospectively enrolled. Indication for WCD was ischaemic cardiomyopathy with LVEF <30% in 950 (82.1%) patients, post-ICD extraction in 119 (10.3%) patients, and waiting for heart transplant in 88 (7.6%) patients (Figure 1). Clinical baseline characteristics of the patients are listed in Table 1. The mean age was 60.0 ± 11.5 years, 974 (84.2%) were males, and mean LVEF was 27.3 ± 8.9%. New York Heart Association (NYHA) status was Class I or II in 671 (58%) patients and Class III or IV in 486 (42%) patients. When looking across the different groups NYHA 3–4 was present in 42% of ischaemic cardiomyopathies, 31% of ICD extraction, and 66% of heart transplantation. A total of 90 patients (7.8%) had renal disease requiring therapy, 119 (10.3%)...
patients had history of atrial fibrillation, 78 (6.7%) had previous stroke. Regarding medical therapies, 1038 (89.7%) patients were prescribed beta-blockers, 1004 (86.8%) angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and 189 (16.3%) amiodarone. Sensitivity analyses were performed according to the period of inclusion (retrospective vs. prospective), and no significant differences were found in baseline characteristics and outcomes (data not shown).

Median WCD usage period was 62 (37–97) days in the overall patient population and differed among patients according to WCD indication with a median period of 64 (38–98) days for patients with ischaemic cardiomyopathy, 44 (27–70) days for patients after ICD extraction, and 77 (43–108) days for pre-transplant patients ($P < 0.001$).

### Table 1  Clinical characteristics of patients at WCD initiation ($n = 1157$)

| Variables                        | 60 ± 12 | 183 (16%) | 27 ± 9 | 685 (59%) | 90 (8%) | 119 (10%) | 78 (7%) | 154 (13%) | 66 (6%) | 1038 (89%) | 189 (16%) | 1004 (86%) |
|----------------------------------|---------|-----------|--------|-----------|---------|-----------|---------|-----------|---------|------------|-----------|------------|
| Age (years)                      |         |           |        |           |         |           |         |           |         |            |           |            |
| Female sex                       |         |           |        |           |         |           |         |           |         |            |           |            |
| Left ventricular ejection fraction (%) |         |           |        |           |         |           |         |           |         |            |           |            |
| Heart failure                    |         |           |        |           |         |           |         |           |         |            |           |            |
| Renal disease                    |         |           |        |           |         |           |         |           |         |            |           |            |
| Atrial fibrillation              |         |           |        |           |         |           |         |           |         |            |           |            |
| Stroke                           |         |           |        |           |         |           |         |           |         |            |           |            |
| Cardiac arrest or resuscitation  |         |           |        |           |         |           |         |           |         |            |           |            |
| Syncope                          |         |           |        |           |         |           |         |           |         |            |           |            |
| Medical therapy                  |         |           |        |           |         |           |         |           |         |            |           |            |
| Beta-blockers                    |         |           |        |           |         |           |         |           |         |            |           |            |
| Amiodarone                       |         |           |        |           |         |           |         |           |         |            |           |            |
| ACE-I/ARBs                       |         |           |        |           |         |           |         |           |         |            |           |            |

ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

### Adherence to wearable cardioverter-defibrillator and impact on perceived health status

The median daily WCD wear time was 23.4 (22.2–23.8) h in the overall population (Figure 2). A total of 162 patients (14.0%) wore the WCD for <20 h per day. In univariate analysis age was significantly lower in patients who wore the WCD <20 h compared to those who wore the WCD ≥20 h (55.7 ± 11.2 vs. 60.8 ± 11.4 years; $P < 0.001$). After multivariable analysis, only younger age was associated with lower compliance (odds ratio (OR) 0.97, 95% confidence interval (CI) 0.95–0.99; $P < 0.01$) (Table 2); WCD indication and sex category were not associated with poor compliance.

Overall, the use of WCD was generally positively associated with health and lifestyle benefits (Figure 3). The two items that patients most agreed with were: ‘Wearing the LifeVest makes me take my condition seriously’ and ‘I follow lifestyle modification recommendations from my physician’ with respectively 88.2% and 92.3% of patients responding ‘Strongly agree’ or ‘Agree’. The two items that users least agreed with were: ‘I sleep significantly better knowing I am protected by the LifeVest’ and ‘LifeVest has given me the confidence to perform exercise or cardiac rehabilitation’ with respectively 52.5% and 49.2% of patients responding ‘Strongly agree’ or ‘Agree’.

### Appropriate, inappropriate therapies, and response button use

During follow-up, a total of 73 arrhythmic events occurred in 55 patients: 42 sustained ventricular tachyarrhythmias (in 36 patients, 31.1%), 24 supraventricular tachycardias/atrial fibrillation or flutter (in 12 patients, 10.0%), and 7 bradycardia or asystole (7 patients, 0.6%). No significant difference was observed according to WCD indication.

A total of 18 participants (1.6%) received at least one appropriate shock: 10 patients for VT and 8 for VF, giving an incidence of appropriate shock of 7.2 (95% CI 3.9–10.5) per 100 patient-years in the overall population (Table 3). According to WCD indication
subgroups, the incidence rate of appropriate therapy was 7.3 (95% CI 3.6–10.9) per 100 patient-years in the ischaemic heart disease group, 6.9 (95% CI 0.9 to 14.8) per 100 patient-years in the post-ICD explantation group and no appropriate therapy was delivered in the pre-transplant group (P-value not calculable). All patients who had shock delivery had their VT/VF episode successfully terminated after a mean number of 1.05 ± 0.22 shocks; only one patient (5.6%) required two shocks to terminate the arrhythmia episode.

Cumulative probability of sustained VT/VF by patient subgroup showed that ventricular tachyrhythmias occurred preferentially during the first month of use. During the first 30 days of use, 26 ventricular arrhythmias (61.9% of all ventricular tachyrhythmias) occurred and led to 11 shocks in 10 patients. Between Day 30 and Day 90, 12 ventricular tachyrhythmias (28.6%) led to 7 shocks in 7 patients.

Eight inappropriate shocks occurred in eight patients (0.7%), giving an incidence rate of 3.2 (95% CI 1.0–5.4) per 100 patient-years. Among the eight inappropriate shocks, six were because of electrocardiogram (ECG) artefact, one because of supraventricular tachycardia and one because of sustained VT that self-terminated just prior to shock.

No inappropriate shock occurred when the deviation button was used. Summary of events, appropriate and inappropriate shocks, and shocks aborted during WCD use are reported in Table 4. A total of 42 patients (159 episodes) aborted ≥ one shock by pressing the patient-response buttons during an alarm. Analysis of EGMs revealed that 31 patients (144/151 episodes) pressed the response button because of VT/VF misclassification and that 11 patients (15 episodes) aborted shocks for well-tolerated VT/VF (out of 42 VT/VF episodes, 35.7%).

**Overall mortality, specific causes of death, and care path at the end of the wearable cardioverter-defibrillator period**

Of the 1157 patients who had the WCD, 24 (2.1%) died during the period of WCD use. Among these patients, in nine who wore the

---

**Table 2** Univariate and multivariate logistic regression on factors associated with compliance (daily wear duration ≥20 h)

|                      | Univariate analysis | Multivariate analysis |
|----------------------|---------------------|-----------------------|
|                      | Odds ratio  | 95% CI     | P-value | Odds ratio  | 95% CI     | P-value   |
| Reference: female gender |          |            |         |          |            |          |
| Male gender          | 0.54       | 0.31–0.93  | 0.03    | 0.54      | 0.28–1.01  | 0.07      |
| Younger age          | 0.96       | 0.95–0.98  | <0.001  | 0.97      | 0.95–0.99  | <0.01     |
| Body mass index      | 0.99       | 0.96–1.03  | 0.81    | 1.01      | 0.96–1.05  | 0.90      |
| Reference: ischaemic WCD indication |          |            |         |          |            |          |
| Post-extraction WCD indication | 0.63     | 0.38–1.03  | 0.07    | 0.76      | 0.38–1.53  | 0.44      |
| Pre-transplantation WCD indication | 0.44     | 0.26–0.75  | 0.003   | 0.82      | 0.41–1.68  | 0.59      |
| Reference: NYHA class I |          |            |         |          |            |          |
| NYHA class II        | 0.66       | 0.35–1.24  | 0.19    | 0.63      | 0.33–1.21  | 0.16      |
| NYHA class III       | 0.59       | 0.31–1.12  | 0.11    | 0.59      | 0.29–1.17  | 0.13      |
| NYHA class IV        | 0.98       | 0.42–2.30  | 0.96    | 0.87      | 0.36–2.11  | 0.75      |
| Left ventricular ejection fraction | 0.99     | 0.98–1.02  | 0.96    | 1.02      | 0.99–1.05  | 0.22      |

NYHA, New York Heart Association; WCD, wearable cardioverter-defibrillator.
WCD at the time of death, non-arrhythmic death was the cause of death in seven, and electrical storm in two. Of the 18 patients who received an appropriate shock and admitted alive, all survived to hospital discharge.

At the end of WCD use, 586 patients (50.6%) were implanted with an ICD. The reasons for non-implantation were 376 (32.5%) LVEF improvement, 69 (6.0%) patient refusal, 20 (1.7%) heart transplantation, 24 (2.1%) death, and 82 (7.1%) other reasons. Among the 950 (82%) patients with WCD indication for ischaemic cardiomyopathy with LVEF <30%, 443 (46.6%) had LVEF improvement ≥35%, with no further need for ICD implantation. During WCD wearing time, 17 (1.5%) patients underwent bypass surgery, 12 (1.0%) patients had implantation of a left ventricular assist device, and 37 (3.2%) patients underwent percutaneous coronary intervention.

**Discussion**

Our real-life findings reinforce previous studies on the efficacy and safety of the WCD in the setting of transient high-risk group in selected patients. Moreover, they emphasize the fact...
that when prescribed appropriately, in concert with adequate patient education and dedicated follow-up using specific remote monitoring system, compliance with WCD is high and the device well-tolerated by the patient.

### Appropriate and inappropriate therapy

Appropriate therapy incidence in the present study was relatively similar to what has been observed in WEARIT-II (5 shocks/100 patient-years) and the German registry (8.4 shocks/100 patient-years), although our population did not include non-ischaemic dilated cardiomyopathies (in accordance with French Social Security Criteria for reimbursement).\(^7,8\) Nevertheless, the appropriate therapy incidence was much lower compared with a recent meta-analysis and more specifically in the post-ICD extraction (6.9 per 100 patient-years) group when compared with the German registry (19.3 per 100 patient-years) which included more than 6000 patients, through old studies which enrolled very high-risk patients.\(^8,12\) On the other hand, WCD was associated with a remarkably low inappropriate therapy rate in the present study (3.2/100 patient-years). Inappropriate shocks by the WCD occur only when there is a combination of a sustained inappropriate classification by the device algorithm and the absence of patient response. In terms of comparison with another device using external ECG discrimination, incidence of inappropriate shocks with the subcutaneous defibrillator is 4.7 per 100 patient-years.\(^13,14\) Although subcutaneous defibrillator and WCD detection algorithms are different, the possibility of shock abortion in the WCD by the patient seems an effective way to reduce inappropriate therapy without an increased risk for untreated VT/VF episodes. Specialized healthcare providers educate patients on how to properly wear the device and how to disable shock delivery using the response buttons. Patient interaction with WCD is useful to avoid inappropriate therapy resulting from supraventricular arrhythmia and artefacts but also to avoid shocks in case of haemodynamically well-tolerated VT which accounted for 35.7% of all sustained VT/VF in our study.

### Adherence and impact on perceived health status

Proper patient education is of paramount importance to ensure optimal efficacy of the device. Compliance was very high, with a median wear time of 23.4 h, similar to US and German observational experiences. These results contrast with the highly debated VEST trial in which average wear time was 14 ± 9.3 h per day.\(^2,15,16\) Possible reasons for this difference may be (i) better patient education; (ii) a closer follow-up through the LifeVest Network telemonitoring platform, with a phone reminder if necessary; (iii) in addition, the context may have played a role—in the current real-life French setting, patients considered WCD to have a clear additional value, since it is reimbursed by the national health French system, contrary to the setting of the VEST trial where the usefulness of WCD was being tested. We found a younger age to be associated with lower compliance. Our results contrast with the recent publication of Olgin\(^17\) which identified ethnicity, marital status, prior percutaneous coronary intervention, and history of cardiac arrest to be associated with adherence. Nevertheless, even if the number of patients enrolled in the present study is lower, we assessed a different population, in which compliance was much better. Lower compliance in younger patients might be explained by several factors, including a more active life incompatible with the WCD. Efforts should be made to improve compliance in this group when delivering WCD. Structured and personalized education, enabling guided patient empowerment, help in improving adherence to WCD.

Overall, users reported a positive experience in the patient questionnaire regarding the WCD. Patients self-reported that using the WCD resulted in taking their disease condition more seriously, which could have a positive impact on their disease management and overall outcome. Indeed, the VEST trial showed that, despite the absence of a statistically significant effect on sudden death, all-cause death was significantly lower in the WCD group.\(^9\)

### Care path at the end of the wearable cardioverter-defibrillator period

Patients with LVEF <30% early after myocardial infarction are a difficult group for decision-making, due to possible transient nature of
risk for SCD and also because very late ventricular arrhythmia occurrence.19 A significant proportion (almost half in our study) of these patients were not implanted with an ICD after optimization of pharmacological therapies, due to their recovery of LVEF. The WCD offers an opportunity for a bridge to recovery or to ICD implantation. Wearable cardioverter-defibrillator allows physicians to correctly evaluate their patients, provide time to achieve optimal pharmacological therapy, thereby improving patient’s management and avoiding unnecessary ICD implantation, which may be associated with significant long-term complications.4,19,20

Limitations
This study has certain limitations due to its observational nature and lack of a control population. Unfortunately, the population was not large enough to identify subgroups at higher risk for appropriate therapies which may help refine candidate selection for the WCD. This call for collaborative studies on WCD in order to test this hypothesis. Moreover, it did not enroll patients with non ischaemic dilated cardiomyopathy according to French reimbursement regulation.

Conclusion
Our observational findings reinforce existing data on efficacy and safety of WCD and furthermore emphasize the high level of patient compliance with WCD in France when specific patient education and remote monitoring are incorporated. Compliance is crucial in ensuring meaningful results from WCD use, and our study’s finding of younger age being associated with poorer compliance, points to the need for additional efforts in this area. Finally, this study also demonstrates the extent to which the use of response button plays a crucial role in the observed low rates of inappropriate WCD shock.

Acknowledgements
We deeply thank all the investigators of the WEARIT-France Study, Laurence Guedon Moreau, Mohanad Mahfoud, Philippe Ritter, Jean-Marc Dupuis, Arab Yalioua, Antoine Dompnier, Marc Goralski, Saïda La Laurence Guedon Moreau, Mohamed Mahfoud, Philippe Ritter, Jean-Marc Dupuis, Arab Yalioua, Antoine Dompnier, Marc Goralski, Saïda La

References
1. Grässner J-T, Lefering R, Koster RW, Masterson S, Böttiger BW, Herlitze J et al. EuReCa ONE-27 Nations, ONE Europe, ONE Registry: a prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe. Resuscitation 2016;105:188–95.
2. Sinhaanant NT, Schilling RJ. Sudden cardiac death and arrhythmias. Arhythm Electrophysiol Rev 2018;7:111–7.
3. Sasson C, Rogers MAM, Dahl J, Kellermann AL. Predictors of survival from out-of-hospital cardiac arrest: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2010;3:63–81.
4. Reek S, Burn H, Roberts FR, Perings C, Epstein AE, Klein HU et al. The wearable cardioverter-defibrillator: current technology and evolving indications. Europace 2017;19:335–45.
5. Lenarczyk R, Potpara TS, Hauga KH, Hernández-Madrid A, Sciaraffia E, Darg N. The use of wearable cardioverter-defibrillators in Europe: results of the European Heart Rhythm Association survey. Europace 2016;18:146–50.
6. Veltmann C, Winter S, Duncker D, Walling NK, Geller JC, Erath JW et al. Protected risk stratification with the wearable cardioverter-defibrillator: results from the WEARIT-II-EUROPE registry. Clin Res Cardiol 2020.
7. Kuttya V, Moss AJ, Klein H, Biton Y, McNitt S, MacKieein B et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation 2015;132:1613–9.
8. Walling NK, Gunther M, Quick S, Pfueckie C, Rotschild F, Smykiewicz SJ et al. Experience with the wearable cardioverter-defibrillator in patients at high risk for sudden cardiac death. Circulation 2016;134:635–43.
9. Olgin JE, Fletcher MJ, Vittinghoff E, Warrance J, Malik R, Morin DP et al. Wearable cardioverter-defibrillator after myocardial infarction. N Engl J Med 2018;379:1205–15.
10. White J, Simon M. Health and lifestyle benefits resulting from wearable cardioverter-defibrillator use. J Innov Card Rhythm Manag 2012;1–2.
11. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007;18:805–35.
12. Masi F, Alfisi AM, Erugu S, Zmial MA, Saleh A, Al-Adamh R et al. Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death: a systematic review and meta-analysis. JACC Clin Electrophysiol 2019;5:152–61.
13. Olde Nordkamp LRA, Brouwer TF, Barr C, Theuns D, Joaquin S, Johansen JB et al. Inappropriate shocks in the subcutaneous ICD: incidence, predictors and management. Int J Cardiol 2015;195:126–9.
14. Burke MC, Gold MR, Knight BP, Barr C, Theuns D, Joaquin S, Johansen JB et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE Study and EFFORTLESS Registry. J Am Coll Cardiol 2015;65:1605–15.
15. Elayi CS, Erath-Honold JW, Jabbari R, Roubille F, Silvan J, Barra S et al. Wearable cardioverter-defibrillator to reduce the transient risk of sudden cardiac death in coronary artery disease. Eurocave 2020. doi:10.1093/europace/euaa052.
16. Kalasar Z, Swenson JH, Capodanno D, Dan G-A, De Maria E, Gorenick B et al. Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous
Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). Europace 2019;21:1603–4.

17. Olgin JE, Lee BK, Vittinghoff E, Morin DP, Zweibel S, Rashba E et al. Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: as-treated and per-protocol analyses. J Cardiovasc Electrophysiol 2020;31:1009–18.

18. Kutyifa V, Vermilye K, Darnée UA, McNitt S, Klein H, Moss AJ. Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death. Europace 2018;20:225–32.

19. Boveda S, Garcia R, Defaye P, Piot O, Narayanan K, Barra S et al. Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death in the real world: Main findings from the French multicentre DAI-PP programme (pilot phase). Arch Cardiovasc Dis 2019;112:523–31.

20. Rischard J, Narayanan K, Garcia R, Marijon E. Prevention of sudden cardiac death and implantable cardioverter defibrillators: Understanding the competitive risk. La Presse Méd 2019;48:1401–5.